| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Therapeutic hypothermia-induced pharmacokinetic alterations on CYP2E1 chlorzoxazone-mediated metabolism in a cardiac arrest rat model.
|
Crit Care Med
|
2006
|
1.59
|
|
2
|
Therapeutic hypothermia decreases phenytoin elimination in children with traumatic brain injury.
|
Crit Care Med
|
2013
|
1.51
|
|
3
|
Anticholinergic activity of 107 medications commonly used by older adults.
|
J Am Geriatr Soc
|
2008
|
1.43
|
|
4
|
Acute 5-HT reuptake blockade potentiates human amygdala reactivity.
|
Neuropsychopharmacology
|
2008
|
1.36
|
|
5
|
Sex, race, and smoking impact olanzapine exposure.
|
J Clin Pharmacol
|
2008
|
1.21
|
|
6
|
Core competencies for research training in the clinical pharmaceutical sciences.
|
Am J Pharm Educ
|
2011
|
1.21
|
|
7
|
Protective effect of the 20-HETE inhibitor HET0016 on brain damage after temporary focal ischemia.
|
J Cereb Blood Flow Metab
|
2006
|
1.18
|
|
8
|
Resampling phase III data to assess phase II trial designs and endpoints.
|
Clin Cancer Res
|
2012
|
1.11
|
|
9
|
An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity.
|
Cancer Chemother Pharmacol
|
2010
|
1.08
|
|
10
|
A model of anticholinergic activity of atypical antipsychotic medications.
|
Schizophr Res
|
2006
|
1.07
|
|
11
|
Endothelin receptor A blockade enhances taxane effects in prostate cancer.
|
Neoplasia
|
2006
|
1.07
|
|
12
|
Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling.
|
Br J Clin Pharmacol
|
2006
|
1.03
|
|
13
|
Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study.
|
Br J Clin Pharmacol
|
2008
|
1.03
|
|
14
|
Mild hypothermia alters midazolam pharmacokinetics in normal healthy volunteers.
|
Drug Metab Dispos
|
2010
|
1.01
|
|
15
|
A time to keep and a time to cast away categories of tumor response.
|
J Clin Oncol
|
2011
|
0.97
|
|
16
|
A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871.
|
Clin Cancer Res
|
2007
|
0.96
|
|
17
|
Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data.
|
Schizophr Bull
|
2012
|
0.94
|
|
18
|
Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study.
|
Schizophr Bull
|
2013
|
0.94
|
|
19
|
The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram.
|
J Clin Pharmacol
|
2009
|
0.93
|
|
20
|
Cardiac arrest and therapeutic hypothermia decrease isoform-specific cytochrome P450 drug metabolism.
|
Drug Metab Dispos
|
2011
|
0.91
|
|
21
|
Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study.
|
J Clin Pharmacol
|
2011
|
0.90
|
|
22
|
Development of a dosage strategy in patients receiving enoxaparin by continuous intravenous infusion using modelling and simulation.
|
Br J Clin Pharmacol
|
2006
|
0.88
|
|
23
|
Predicting relapsing-remitting dynamics in multiple sclerosis using discrete distribution models: a population approach.
|
PLoS One
|
2013
|
0.88
|
|
24
|
Population pharmacokinetic modeling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescents.
|
Ther Drug Monit
|
2012
|
0.86
|
|
25
|
Effect of age, weight, and CYP2C19 genotype on escitalopram exposure.
|
J Clin Pharmacol
|
2009
|
0.86
|
|
26
|
Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study.
|
Ther Drug Monit
|
2012
|
0.86
|
|
27
|
The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance).
|
Pharmacogenet Genomics
|
2013
|
0.85
|
|
28
|
Sex differences in the pharmacokinetics and pharmacodynamics of antidepressants: an updated review.
|
Gend Med
|
2009
|
0.85
|
|
29
|
Translocator protein blockade reduces prostate tumor growth.
|
Clin Cancer Res
|
2009
|
0.85
|
|
30
|
Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advanced malignancies.
|
Cancer Chemother Pharmacol
|
2004
|
0.85
|
|
31
|
Age and sex impact clozapine plasma concentrations in inpatients and outpatients with schizophrenia.
|
Am J Geriatr Psychiatry
|
2012
|
0.84
|
|
32
|
Population pharmacokinetics in geriatric psychiatry.
|
Am J Geriatr Psychiatry
|
2006
|
0.83
|
|
33
|
Relevance of assessing drug concentration exposure in pharmacogenetic and imaging studies.
|
J Psychopharmacol
|
2006
|
0.83
|
|
34
|
Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study.
|
Ther Drug Monit
|
2009
|
0.83
|
|
35
|
Role of endothelin axis in progression to aggressive phenotype of prostate adenocarcinoma.
|
Prostate
|
2005
|
0.82
|
|
36
|
Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: a cross-sectional study.
|
Prog Neuropsychopharmacol Biol Psychiatry
|
2011
|
0.81
|
|
37
|
Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking.
|
J Clin Pharmacol
|
2009
|
0.81
|
|
38
|
Pharmacokinetic-pharmacodynamic analysis of the static allodynia response to pregabalin and sildenafil in a rat model of neuropathic pain.
|
J Pharmacol Exp Ther
|
2010
|
0.80
|
|
39
|
Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building.
|
J Pharmacokinet Pharmacodyn
|
2012
|
0.80
|
|
40
|
Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.
|
Prog Neuropsychopharmacol Biol Psychiatry
|
2013
|
0.80
|
|
41
|
Estimated dopamine D₂ receptor occupancy and remission in schizophrenia: analysis of the CATIE data.
|
J Clin Psychopharmacol
|
2013
|
0.79
|
|
42
|
Bayesian model of Hamilton Depression Rating Score (HDRS) with memantine augmentation in bipolar depression.
|
Br J Clin Pharmacol
|
2013
|
0.79
|
|
43
|
Estimated dopamine D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia: an analysis of the CATIE data.
|
Schizophr Res
|
2013
|
0.78
|
|
44
|
Impaired 6-hydroxychlorzoxazone elimination in patients with kidney disease: Implication for cytochrome P450 2E1 pharmacogenetic studies.
|
Clin Pharmacol Ther
|
2003
|
0.77
|
|
45
|
Relation of serotonin transporter genetic variation to efficacy of escitalopram for generalized anxiety disorder in older adults.
|
J Clin Psychopharmacol
|
2010
|
0.77
|
|
46
|
Nicotine and cotinine exposure from electronic cigarettes: a population approach.
|
Clin Pharmacokinet
|
2015
|
0.77
|
|
47
|
Adherence to escitalopram treatment in depression: a study of electronically compiled dosing histories in the 'Depression: the search for phenotypes' study.
|
Int Clin Psychopharmacol
|
2012
|
0.76
|
|
48
|
Population pharmacokinetic modeling of sertraline treatment in patients with Alzheimer disease: the DIADS-2 study.
|
J Clin Pharmacol
|
2013
|
0.76
|
|
49
|
Pharmacokinetics in geriatric psychiatry.
|
Curr Psychiatry Rep
|
2008
|
0.76
|
|
50
|
Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice.
|
Br J Clin Pharmacol
|
2014
|
0.76
|
|
51
|
Clinical trial simulation to evaluate population pharmacokinetics and food effect: capturing abiraterone and nilotinib exposures.
|
J Clin Pharmacol
|
2015
|
0.75
|
|
52
|
Performance of Cpred/Cobs concentration ratios as a metric reflecting adherence to antidepressant drug therapy.
|
Neuropsychiatr Dis Treat
|
2011
|
0.75
|
|
53
|
Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors.
|
Cancer Chemother Pharmacol
|
2012
|
0.75
|
|
54
|
Impact of once- versus twice-daily perphenazine dosing on clinical outcomes: an analysis of the CATIE data.
|
J Clin Psychiatry
|
2014
|
0.75
|
|
55
|
Dose reduction of risperidone and olanzapine and estimated dopamine D₂ receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study.
|
J Clin Psychiatry
|
2014
|
0.75
|
|
56
|
Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-Alzheimer's disease trial.
|
J Clin Psychopharmacol
|
2010
|
0.75
|